This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kao, L. M. Articles by Kelley, M. F. Search for Related Content PubMed PubMed Citation Articles by Kao, L. M. Articles by Kelley, M. F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2006, p. 3535-3542, Vol. 50, No. 11
0066-4804/06/$08.00+0     doi:10.1128/AAC.00090-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Pharmacokinetic Considerations and Efficacy of Levofloxacin in an Inhalational Anthrax (Postexposure) Rhesus Monkey Model

Johnson & Johnson Pharmaceutical Research and Development, LLC, Raritan, New Jersey,¹ Battelle Memorial Institute, West Jefferson, Ohio,² Covance Laboratories Inc., 3301 Kinsman Boulevard, Madison, Wisconsin 53704,³ Ordway Research Institute, Albany, New York,⁴ Johnson & Johnson Pharmaceutical Research and Development, LLC, Beerse, Belgium,⁵ Johnson & Johnson Pharmaceutical Research and Development, LLC, Spring House, Pennsylvania⁶

Received 21 January 2006/ Returned for modification 10 April 2006/ Accepted 21 July 2006

Because the treatment of inhalational anthrax cannot be studied in human clinical trials, it is necessary to conduct efficacy studies using a rhesus monkey model. However, the half-life of levofloxacin was approximately three times shorter in rhesus monkeys than in humans. Computer simulations to match plasma concentration profile, area under the concentration-time curve (AUC), and time above MIC for a human oral dose of 500 mg levofloxacin once a day identified a dosing regimen in rhesus monkeys that would most closely match human exposure: 15 mg/kg followed by 4 mg/kg administered 12 h later. Approximately 24 h following inhalational exposure to approximately 49 times the 50% lethal doses of Bacillus anthracis (Ames strain), monkeys were treated daily with vehicle, levofloxacin, or ciprofloxacin for 30 days. Ciprofloxacin was administered at 16 mg/kg twice a day. Following the 30-day treatment, monkeys were observed for 70 days. Nine of 10 control monkeys died within 9 days of exposure. No clinical signs were observed in fluoroquinolone-treated monkeys during the 30 treatment days. One monkey died 8 days after levofloxacin treatment, and two monkeys from the ciprofloxacin group died 27 and 36 days posttreatment, respectively. These deaths were probably related to the germination of residual spores. B. anthracis was positively cultured from several tissues from the three fluoroquinolone-treated monkeys that died. MICs of levofloxacin and ciprofloxacin from these cultures were comparable to those from the inoculating strain. These data demonstrate that a humanized dosing regimen of levofloxacin was effective in preventing morbidity and mortality from inhalational anthrax in rhesus monkeys and did not select for resistance.